Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance-Reference-Cited by-同舟云学术

Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

Published:2018-04-26 Issue:6 Volume:9 Page:1323-1332
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Matsuba Ikuro¹^ORCID,Matsuba Ren²,Ishibashi Shun³,Yamashita Shizuya⁴⁵,Arai Hidenori⁶,Yokote Koutaro⁷,Suganami Hideki⁸,Araki Eiichi⁹

Affiliation:

1. Matsuba Clinic; Kanagawa Japan

2. Department of Internal Medicine; Division of Metabolism and Endocrinology; St. Marianna University School of Medicine; Kanagawa Japan

3. Division of Endocrinology and Metabolism; Department of Medicine; Jichi Medical University; Tochigi Japan

4. Department of Community Medicine and Department of Cardiovascular Medicine; Osaka University Graduate School of Medicine; Osaka Japan

5. Rinku General Medical Center; Osaka Japan

6. National Center for Geriatrics and Gerontology; Aichi Japan

7. Department of Clinical Cell Biology and Medicine; Chiba University Graduate School of Medicine; Chiba Japan

8. Clinical Data Science Department; Kowa Company, Ltd.; Tokyo Japan

9. Department of Metabolic Medicine; Faculty of Life Sciences; Kumamoto University; Kumamoto Japan

Funder

Kowa Company, Ltd

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdi.12845/fullpdf

Reference44 articles.

1. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study;Martin;Lancet,1992

2. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009;DeFronzo;Diabetologia,2010

3. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study;Robins;Arterioscler Thromb Vasc Biol,2011

4. Peroxisome proliferator-activated receptors: nuclear control of metabolism;Desvergne;Endocr Rev,1999

5. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus;Bajaj;Diabetologia,2007

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of Pemafibrate administration in patients with dyslipidemia: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials.;2024-07-16

2. Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial;European Journal of Clinical Investigation;2024-04-25

3. Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome;Heart and Vessels;2024-02-23

4. Pemafibrate;Clinical Lipidology;2024

5. Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia;Journal of Clinical Medicine;2023-11-03